Patients’ knowledge and perspectives on wet age-related macular degeneration and its treatment by Kandula, Sushma et al.
© 2010 Kandula et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2010:4 375–381
Clinical Ophthalmology
O R I G I N A L   R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
375
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Patients’ knowledge and perspectives on wet  
age-related macular degeneration and its 
treatment
Sushma Kandula1 
Jeffrey C Lamkin1 
Teresa Albanese2 
Deepak P Edward1
1Department of Ophthalmology, 
2Health Service Research and 
Education Institute, SUMMA Health 
System, Akron OH, USA
Correspondence: Sushma Kandula
75 Arch Street, Suite 512,   Akron OH 
44312, USA
Email kandula7@yahoo.com
Summary: There have been no studies examining the level of understanding age-related macular 
degeneration (ARMD) patients have about their disease, or their perceptions about intraocular 
injections as treatment. In this study, patient knowledge about ARMD risk factors was low but 
patients appeared more optimistic than fearful when confronted with intraocular antivascular 
endothelial growth factor (anti-VEGF) injections as treatment.
Purpose: In recent years there has been an increase in our understanding of wet ARMD, and a 
dramatic shift in the treatment paradigm. However, to our knowledge, no studies have examined 
how much ARMD patients understand their disease, or how they feel about receiving intraocular 
injections as treatment. The primary objectives of this study are to identify areas in which ARMD 
patients may be uninformed about their disease, and to recognize specific fears or expectations 
that patients may have regarding treatment with intraocular anti-VEGF injections.
Design: Prospective, survey-based study.
Methods: This is a prospective survey-based study. An anonymous 32-item questionnaire was 
compiled and distributed to patients with wet ARMD who underwent at least one intraocular 
anti-VEGF injection. Eighty-three patients from a retina practice in a suburban setting com-
pleted the questionnaire that gauged both their knowledge of ARMD and their perspectives on 
its treatment. Data was analyzed using chi-square testing.
Results: Seventy-eight percent of patients received most of their knowledge of ARMD from 
their physician. Eighty-nine percent of patients prefer to receive more information on ARMD, 
if needed, directly from their physician. Only 21%, 48%, 37%, 48%, and 36%, respectively, 
correctly identified how diet, special vitamins, high blood pressure, family history, and smok-
ing can affect ARMD. Sixty percent felt somewhat afraid or very afraid about getting their 
first intraocular injection but this did not correlate with pain or discomfort during treatment 
(P = 0.075, P = 0.117). Eighty-nine percent were very satisfied and 11% were somewhat 
satisfied with the explanation their physician gave them about the injections. Eighty percent 
reported feeling hopeful (significantly more than any other emotion) when they were first told 
they needed an intraocular injection for treatment of their disease.
Conclusions: Knowledge of risk factors and risk factor modification among patients with 
ARMD is low. Since the vast majority of ARMD patients prefer to receive information 
directly from their physician, patient education is crucial in improving risk factor modi-
fication and alleviating fears of treatment. With the advent of anti-VEGF agents, patients 
appear more hopeful of regaining vision than they are fearful of treatment with intraocular 
injections.
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Introduction
The number of adults with ARMD is expected to increase by 
50% to 3 million people by the year 2020.1 Rein et al recently 
published a study on ARMD prevalence in the United States 
and predicted 17.8 million cases by the year 2050.2 This surge 
in ARMD cases will be largely due to the significant increase 
in the population of Americans aged 65 years and older, which 
is projected to exceed 82 million by the year 2050.3
Previously, treatments for ARMD (such as laser) were 
ineffective and visual loss was inevitable. However, the 
emergence of intraocular injections of VEGF inhibitors has 
been effective in neovascular macular degeneration which 
is responsible for the most severe vision loss that occurs in 
ARMD patients. In many cases, these revolutionary anti-
VEGF inhibitors have actually been shown to improve vision 
in some patients.4–8
Studies have long established the impact of ARMD on 
the quality of life. The National Eye Institute (NEI) generated 
a questionnaire (Visual Functioning Questionnaire 25) that 
measured activities of daily living, mental health, and quality 
of life among patients diagnosed with varying degrees of 
ARMD.9,10 The severity of disease was found to be directly 
proportional to the decrease in quality of life. Hence, the 
diagnosis of ARMD can be grim for patients, but there are 
several modifiable risk factors such as smoking and diet that 
can impact or impede the progression of ARMD.11–27 How-
ever, no studies to our knowledge have evaluated how much 
patients with ARMD understand about their disease. Addi-
tionally, although the advent of anti-VEGF injection therapies 
has given new hope for patients with ARMD, no studies have 
investigated how patients view such treatments. The thought 
of any injection with a needle instills fear and uncertainty in 
many patients.28 The neovascular ARMD patient in particular 
is often expected to make frequent visits for repeat injections 
(with risks such as infection, bleeding, and vision loss in 
and of itself), and undergo multiple tests for monitoring the 
condition without guarantee of vision preservation. Further-
more, health care plans often do not completely cover these 
treatments, thereby leaving some patients with significant 
financial burden and possible reluctance to begin or continue 
therapy. We wonder if the above issues may influence thera-
peutic outcomes. This proposed study also aims to elucidate 
specific areas in which clinicians may need to better educate 
and counsel their patients with ARMD.
Methods
A 32-item questionnaire approved by the SUMMA Institu-
tional Review Board and compliant with the Health Insurance 
Portability and Accountability Act (HIPAA) was given to 
neovascular ARMD patients who had received at least one 
anti-VEGF injection. Patients were asked to participate in the 
survey while awaiting their scheduled appointment in the retina 
clinic. The retina clinic is a three-physician private practice 
group located in a suburban setting. The main objective of the 
questionnaire was to gauge patients’ knowledge of ARMD, 
and their feelings and expectations regarding treatment with 
intraocular anti-VEGF injections. The questions were divided 
into three sections and represented patient demographics, 
patient knowledge, and patient perspectives. The survey instru-
ment excluded personally identifying information. Completed 
questionnaires were randomly placed into a closed box to 
ensure privacy.
Inclusion criteria consisted of any patient diagnosed 
with wet macular degeneration who had already received a 
minimum of one anti-VEGF injection. Patients who received 
past, alternative treatments for macular degeneration, such as 
laser or surgery, were also considered as long as they had met 
the inclusion criteria indicated above. Exclusion criteria were 
patients who did not have the wet form of macular degenera-
tion, or patients with wet macular degeneration who had not 
yet received an injection. Patients qualifying for the study who 
completed a questionnaire received reimbursement (US $10) to 
improve compliance. Questionnaire responses were recorded 
at the end of survey collection and analyzed for descriptive 
and associative analysis with chi-square testing.
Results
Demographic information of the study group is presented in 
Table 1. The average age of the patients was 82 years with 
a range between 58 and 96 years. Sixty-eight percent of 
respondents were female and over 96% were Caucasian. All 
patients reported English as being their primary language. 
Of the patients included in the study, 75% had someone 
drive them to their appointments, 18% walked or drove 
themselves, and 5% took public transportation. Twelve 
percent of patients reported having ARMD for less than a 
year, 58% had the disease for between 1 and 5 years, 17% 
for 5–10 years, and 6% for more than 10 years. The duration 
of disease did not correlate with appropriate knowledge of 
disease. Furthermore, less than 46% (45.8%) of patients 
reported taking vitamins for their ARMD and 4.8% were 
current smokers. Females appeared more likely to take daily 
vitamins for their ARMD (P = 0.013). Sixty percent reported 
that ARMD had mildly or moderately affected their quality 
of life and 16% reported that it had extremely affected their 
quality of life.Clinical Ophthalmology 2010:4 377
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Figure 1 demonstrates how most patients received their 
knowledge of ARMD. By far, most patients (78.3%) learned 
about ARMD primarily from their doctor. Although 77% felt 
they were moderately or very knowledgeable about ARMD, 
only 21%, 48%, 37%, 48%, and 36%, of patients respectively, 
correctly identified how diet, special vitamins, high blood 
pressure, family history, and smoking can affect ARMD 
(Figure 2). The vast majority of patients (89%) preferred to 
receive more information about macular degeneration from 
their retinal physician than any other source (eg, internet, 
videos/DVD, pamphlet).
Eighty-nine percent of patients were very satisfied with 
the counseling given by the retinal physician prior to the 
intravitreal injection. Figure 3 summarizes how patients 
felt when they were first told they needed an intraocular 
  injection to treat the ARMD. By far the most common emo-
tion was “hopeful” (80%). Only 6% and 22% respectively 
felt that any of the injections were painful or uncomfortable 
and this feeling did not correlate with being “afraid” or 
“very afraid” upon learning that an injection was needed 
in the eye. There were also no statistically significant 
  correlations between feeling pain or discomfort with sex, 
age, or living alone. Although 51% were “somewhat afraid” 
and 10% were “very afraid” about getting their first injec-
tion, no patients reported missing appointments because 
of trepidation of receiving an injection into the eye. Most 
patients (75%) actually had a better than expected experi-
ence when receiving their first injection. Over 66% of 
patients also reported that they were less afraid before going 
in for their second injection. In terms of visual outcome, 
47% of patients reported some improvement in vision, 
and 27% claimed very good improvement in vision since 
receiving the injections (Figure 4). Finally, 58% of patients 
would prefer taking pills at home as opposed to receiving 
injections in the office if such a treatment were available. 
Not surprisingly, patients who reported pain or discomfort 
during the injection were more likely to want to take pills 
for their ARMD instead of injections (P = 0.03).
Discussion
Although the advent of new anti-VEGF agents such as 
ranibizumab and bevacizumab has given renewed hope to 
ARMD patients, there should also be emphasis on risk factor 
modification to enhance the ability of these new agents, and 
to prevent further progression of disease (including in the 
contralateral eye). Risk factor modification takes into account 
smoking, blood pressure control, antioxidant vitamin intake, 
and diet. Several studies have demonstrated that smoking is a 
very strong risk factor for progression of ARMD but less than 
35% of patients in this study recognized it as a risk factor.15–18 
In a more recent Beaver Dam Eye Study, an increase in 
systolic blood pressure greater than 5 mm Hg resulted in an 
increased risk of advanced ARMD by fivefold.29 In addition, 
reports of the Age-Related Eye Disease Study (AREDS) 
established that the intake of omega-3 fatty acids, fish, and 
sources of lutein and zeaxanthine (dark green leafy veg-
etables) decreased progression to advanced ARMD by 39% 
and 54% respectively.23,24 However, only 37% of patients in 
this study identified blood pressure as a risk factor, and even 
fewer (22%) were aware of diet as a risk factor. AREDS also 
reported that patients with moderate disease can significantly 
decrease (by 25%) the progression of ARMD by taking a 
specific combination (AREDS formulation) of vitamin C, 
vitamin E, beta-carotene, zinc, and copper in pill form every 
day.29 Again, only 48% of patients in our study were aware of 
this, and the number may be even lower as some patients may 
have mistaken it for a simple multivitamin. In fact, the stud-
ies that have investigated patient use of AREDS-formulation 
vitamins have found that a significant number who do report 
Table 1 Basic patient demographic information
  % of patients
Sex
  Male
  Female
32
68
Age group
  50–60
  60–70
  70–80
  80
1
4
31
64
Ethnicity
  Caucasian
  Other
96.4
1.2
Duration of ARMD
  1 year
  1–5 years
  5–10 years
  10 years
12
57.8
16.9
6
Smoking
  Yes
  No
4.8
92.8
ARMD vitamins taken daily
  Yes
  No
45.8
51.8
Live alone
  Yes
  No
47
53Clinical Ophthalmology 2010:4 378
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vitamin usage actually use suboptimal dosages.30–33 Although 
elevated cholesterol has been reported as a risk factor there 
are conflicting studies in the literature and therefore this was 
not included in the questionnaire.34,35
The results of this study suggest that the knowledge 
of risk factors and risk factor modification among ARMD 
patients is low and may be important in disease progression 
or prevention. Our questionnaire asked the patients about 
ways that they would prefer to improve knowledge about 
their ARMD. Since the vast majority of ARMD patients 
(90%) preferred to receive information directly from their 
physician, patient education by physicians may be crucial 
in improving risk factor modification. This may be more 
challenging with hearing-impaired elderly patients and in 
settings that limit appointment times. It is recommended that 
the patient be given a simplified explanation of the disease 
process and its risk factors by the physician, and to also 
involve family members in the discussion. Using a pamphlet 
may facilitate the discussion, and can serve the patient and 
his or her family members as a point of reference after they 
leave the office. The physicians in this retina practice gen-
erally used this method of patient education but our results 
suggest that greater emphasis be placed on risk factor modi-
fication in future patient discussions. Although the style of 
patient education naturally differs between the physicians 
in this practice, all used a standardized pamphlet from the 
American Academy of Ophthalmology as a teaching aid as 
well as a customary intravitreal injection consent form that 
detailed all the risks and benefits of the procedure. Serious 
risks were outlined including infection, vitreous hemorrhage, 
retinal tear or detachment, cataract, and glaucoma. Other less 
serious risks such as subconjunctival hemorrhage, eye pain, 
corneal abrasion, floaters, and inflammation of the eye were 
also detailed in the consent form.
As mentioned previously, the introduction of anti-VEGF 
agents has revolutionized its treatment. However, of frequent 
concern is how the injections are administered. In this study a 
significant number of patients (60%) appeared to show some 
level of trepidation prior to receiving these injections. To the 
best of our knowledge no studies have evaluated the fear of 
needles in ophthalmology patients. There are, however, studies 
demonstrating decreased compliance with treatment in patients 
requiring injections in other specialties.22,36,37 Although none of 
the patients in this study reported missing an appointment for 
fear of the injection (or cost for that matter), the inherent sam-
pling bias of an in-office questionnaire, as well as small sample 
size, precludes these from being noteworthy findings.
A large percentage (89%) reported being “very satisfied” 
with the explanation that was given by their physician on 
how the injections were given. Before assuming adequacy 
it should be noted that ARMD focus group studies find that 
most elderly patients tend to provide very positive reviews in 
an effort to please their physicians.38 However, given the fact 
that the respondents were anonymous, this was still a reas-
suring percentage. Although only a small minority of patients 
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reported pain or discomfort from receiving the injections it still 
appeared that the majority (58%) would prefer to take a pill 
at home as opposed to receiving injections in the office. We 
wondered why this number was not higher and postulated that 
most of these were elderly patients who were more likely to be 
on multiple pill regimens. Thus, having an injection into the 
eye not only decreased the need to take one additional daily 
pill but it also guaranteed direct delivery into the diseased site 
with minimal systemic side effects. One surprising result was 
that by far the most prevalent emotion upon hearing the need 
for an injection was “hopeful” (even more so than “afraid”). 
This result can be explained in part by a study done by Owsley 
et al which found that people with ARMD are generally 
more optimistic in an effort to improve their depression and 
well-being.39 However, that study was completed before the 
widespread use of anti-VEGF agents in ARMD. For a disease 
that has a potentially crushing impact on quality of life, 
previous treatments (laser photocoagulation, photodynamic 
therapy) were rather disappointing and rarely resulted in 
visual improvement. The currently approved anti-VEGF agent 
ranibizumab has demonstrated significant visual improvement 
in 25%–30% of patients, and over 90% of patients maintain 
their vision or have some improvement.40 This unprecedented 
success in ARMD treatment has greatly contributed to patients 
being much more hopeful of regaining vision than they are 
fearful of treatment with intraocular injections. A recent 
summary of clinical trials has determined that there was a 
greater visual benefit in administering ranibizumab injections Clinical Ophthalmology 2010:4 380
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on a monthly basis.41 This increased frequency makes it even 
more important to gauge patients’ attitudes towards these 
injections and improve risk factor modification to ensure that 
patients are maximizing treatment outcome.
This study has some limitations. One of the goals of the 
study was to determine if patients felt the injections as being 
painful or uncomfortable. Hence the inclusion criteria required 
that a patient must have undergone at least one injection 
anytime during their treatment. Some patient responses may 
have been biased as a result of the retrospective nature of the 
question. Furthermore, there was no questionnaire given to 
patients prior to their first injection, and no attempt was made 
to contact patients who may have refused injections. This 
information would have been useful in possibly obtaining 
less-biased responses as well as pinpointing specific reasons 
for refusing treatment. We also found that over 70% of our 
patients come to their appointments by having someone else 
drive them. Nevertheless, in this study, compliance did not 
appear to be affected by cost of treatment, fear of treatment, 
or lack of access to resources or care. This is to be generally 
expected in a suburban private practice with mostly insured 
patients. However, we wonder if the above issues may be of 
more concern in a different setting where access to facilities 
is problematic (family members unable to drive and sit with 
patients for frequent exams and injections), and lack of resources 
may preclude patients from obtaining the care that they need. 
Perhaps a multicentric study design that would reduce bias, and 
include a larger and more diverse socioeconomic population 
may help provide the answers to those questions.
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